Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! 

China Clinical Trials 2017

Analysis of IND and NDA applications and approvals in China 2011-2017

Download free report on life science investment in China

Newsummit Biopharma Files for $80 Million NYSE IPO

publication date: Feb 25, 2012
Newsummit Biopharma, a Shanghai-based CRO offering pre-clinical drug development services, filed to raise up to $80 million in a New York Stock Exchange IPO. The company has offices in five technology parks around China, and is headquartered in Shanghai's Zhangjiang Hi-Tech Park. Newsummit aims to be a one-stop solution for bringing a drug candidate or medical device through an IND (or NDA) filing, after the initial work on the product has been completed. The company uses a network of 99 service providers for most tasks. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China